AI-Native Scoping Reviews & Evidence Mapping

Iliac artery endofibrosis is a hidden performance-limiting vascular disease of endurance athletes, often missed by resting tests but revealed by post-exercise hemodynamics and dynamic imaging. The full SAIMSARA evidence map gives clinicians, researchers, and LLM agents a structured, reference-linked view of diagnosis, mechanisms, open surgery, endovascular limits, and return-to-sport outcomes — ready for human reading and machine reasoning.

This SAIMSARA review maps 261 original studies comparing AVF and AVG for hemodialysis access, showing where fistulas dominate on durability, infection, mortality, and cost — and where grafts may be clinically preferable for frail, catheter-dependent, or poor-vein patients. The full evidence map gives humans and LLMs a structured, reference-linked view of patency, complications, survival, economics, patient subgroups, and access-selection trade-offs — ready for clinical reading, reasoning, and machine-readable evidence use.

Postoperative complications in vascular surgery are not a single risk — they are a procedure-specific spectrum dominated by cardiac injury, wound/groin infection, renal dysfunction, pulmonary failure, and post-discharge events. This review maps where the danger concentrates and why generic risk calculators are insufficient for modern vascular practice.

TEVAR is no longer just a less invasive alternative to open repair — across type B dissection, traumatic injury, and thoracic aneurysm, it has become a strategy whose success depends on timing, landing-zone judgment, branch preservation, and complication control. This review shows where TEVAR clearly wins, where the evidence is still conflicted, and which technical decisions most strongly shape survival, remodeling, and long-term failure.

This review shows that TCAR is not just another carotid stenting technique, but a potentially safer endovascular strategy with a recurrent signal for lower stroke and death risk than transfemoral CAS, especially when neuroprotection matters most. The full read is worth it because it clarifies where that advantage looks strongest, where the evidence is still mixed, and which anatomical, symptomatic, and restenotic subgroups may truly benefit from TCAR.

This paper shows that statins remain one of the strongest cardiovascular therapies, consistently linked to fewer major events and lower mortality across very large populations, but not without trade-offs such as diabetes risk, muscle symptoms, and rises in lipoprotein(a). The full paper is worth reading because it shows where the benefit is most convincing, where the risks matter most, and how to think more clearly about the real balance between protection and harm.

This review shows that rare vascular diseases are not just isolated curiosities: many are driven by shared pathways of vascular fragility, abnormal remodeling, and delayed diagnosis. It highlights where genetics, imaging, and targeted therapies are already turning rare vascular biology into practical clinical decisions.

Rural Australians have more heart disease and worse outcomes than people in metropolitan areas. Better prevention, telehealth, and regional cardiac care may help reduce this gap, but the available evidence is still insufficient.

WIfI combines true biological risk signals such as ischemia with limb-level consequences such as wound burden and infection to answer the central clinical question in PAD: is limb salvage still realistically achievable? This evidence map shows how WIfI stage translates into real-world amputation risk across clinical scenarios, and where its predictive value becomes strongest in modern decision-making.

PAD is not just a leg-artery disease — it is a powerful warning sign for future death, cardiovascular events, limb loss, and frailty. This review maps which signals matter most for prognosis, from MALE, polyvascular disease, diabetes and CKD to biomarkers, nutrition scores, exercise capacity, and machine-learning risk prediction.

This review shows that PAD is not a niche vascular diagnosis but a massive, underrecognized global burden that concentrates sharply in diabetes, kidney disease, stroke, and other high-risk populations while often remaining clinically silent. The full read is worth it because it maps where PAD prevalence is truly highest, why reported rates vary so widely, and which patient groups should trigger much earlier ABI-based case finding.

PAD is not just blocked arteries — this review shows it as a biologically complex disease driven by endothelial failure, oxidative stress, metabolic myopathy, mitochondrial dysfunction, and emerging signals from gut metabolites, extracellular vesicles, and non-coding RNA pathways. The full read is worth it because it maps where the strongest mechanistic evidence lies, which biomarkers may matter next, and which pathophysiologic signals could reshape future PAD diagnostics and targeted therapy.